Mini Cleanroom for the Manufacture of Advanced Therapy Medicinal Products (ATMP): Bioengineered Corneal Epithelium

Author:

Berisa-Prado SilviaORCID,Vázquez NataliaORCID,Chacón Manuel,Persinal-Medina MairobiORCID,Alonso-Alonso Sergio,Baamonde Begoña,Alfonso José F.,Fernández-Vega-Cueto Luis,Merayo-Lloves Jesús,Meana ÁlvaroORCID

Abstract

Among several requirements for the manufacture of Advanced Therapy Medicinal Products (ATMP) are: following the guidelines of a pharmaceutical quality system, complying with Good Manufacturing Practice (GMP) and access to a cleanroom fulfilling strict environmental conditions (Class A work area and Class B environment). This makes ATMP expensive. Moreover, the production of many of these therapeutic products may also be unprofitable, as in most cases their use is limited to a few patients and to a single batch per manufacturing unit. To reduce costs, ATMP may be produced in a scaled-down system isolated from the external environment (isolator), allowing for placement of this facility in a Class D environment, which is much more permissive and less costly. In this work, we confirm that it is possible to manufacture bioengineered corneal epithelium inside an isolator while fulfilling all the safety assurance standards at an affordable cost for patients. This small-scale ultra-clean working environment complies with GMP guidelines and could be a solution for the high costs associated with conventional cleanroom ATMP production.

Funder

Government of Principado de Asturias (FICYT) co-financed by the European Regional Development Fund (FEDER) and by Fundación Telefónica

Publisher

MDPI AG

Subject

Pharmaceutical Science

Reference22 articles.

1. Navigating Market Authorization: The Path Holoclar Took to Become the First Stem Cell Product Approved in the European Union

2. A completely human-derived biomaterial mimicking limbal niche: Platelet-rich fibrin gel

3. Autologous method for ex vivo expansion of human limbal epithelial progenitor cells based on plasma rich in growth factors technology

4. Regulation (EC) No. 1394/2007 of the European Parliament and of the Council of 13 November 2007 on Advanced Therapy. Medicinal Products and Amending Directive 2001/83/EC and Regulation (EC) No. 726/https://eur-lex.europa.eu/legal-content/ES/TXT/?uri=CELEX%3A32007R1394

5. Real Decreto 477/2014, de 13 de Junio, Por el Que se Regula la Autorización de Medicamentos de Terapia Avanzada de Fabricación no Industrialhttps://www.boe.es/eli/es/rd/2014/06/13/477

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3